Bionomics receives BNC105 Phase II trial results
THE PHARMACY: Bionomics Limited (ASX: BNO) has announced the results of the DISRUPTOR-1 trial of BNC105 in patients with metastatic renal cancer. “The DISRUPTOR-1 trial has been the first of its kind in testing the combination of an mTOR inhibitor with a vascular disrupting agent in renal cancer, with the prospect of adding a new […]




